FLT3-specific chimeric antigen receptors and methods using same

US11299546B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Christopher D. Chien · Falls Church, US
• Terry J. Fry · Denver, US

Key dates

• Filing date: May 26, 2017
• Grant date: Apr 12, 2022
• Expiry date: Mar 22, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/715
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An embodiment of the invention provides a chimeric antigen receptor (C AR) comprising an antigen binding domain specific for FLT3, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.